Literature DB >> 82473

Germ cell tumors (II): VAB II in metastatic testicular cancer.

E Cheng, E Cvitkovic, R E Wittes, R B Golbey.   

Abstract

Between June 1974 and January 1976, 50 patients with metastatic non-seminometous testicular carcinoma were treated with the VAB II protocol. The induction phase consisted of vinblastine (0.4 mg/kg) and actinomycin D (0.02 mg/kg) on day 1. Bleomycin (0.5 mg/kg) was given by continuous infusion for 7 days, and cis-diammine-dichloroplatinum (II) (DDP) (1 mg/kg) was given on day 8. A weekly maintenance of vinblastine and bleomycin, with actinomycin D and DDP on a rotating schedule was given followed by vinblastine, actinomycin D and chlorambucil every 3--4 weeks. Therapy was discontinued after 30--36 months of treatment in the face of continued remission. The response rate was 50% CR, 34% PR with 60% CR and 36% PR in previously untreated patients. Second-look surgery and excision of residual lesions was performed in selected cases. Alopecia, mucositis, nausea, and vomiting were universal. One patient died in the postsurgical period of toxicity from the combination of bleomycin and high concentrations of oxygen. There were seven instances of allergic reactions to DDP. Eleven of 25 complete responders and 4 partial or minor responders who underwent excision of stable disease remain alive from 19 to 35 months following start of therapy, 12 of them without evidence of disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 82473     DOI: 10.1002/1097-0142(197811)42:5<2162::aid-cncr2820420512>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Current impact of adjuvant chemotherapy in resectable cancer.

Authors:  A Rossi; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Chemotherapy for non-seminomatous germ-cell tumours.

Authors:  P M Wilkinson
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

3.  Advances in pathology and immunocytochemistry.

Authors:  E Heyderman
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

Review 4.  Commentary: combination chemotherapy of nonseminomatous testicular cancer.

Authors:  S K Carter; F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells.

Authors:  Caryl J Giuliano; Sarah J Freemantle; Michael J Spinella
Journal:  Curr Cancer Ther Rev       Date:  2006-08-01

6.  [Sequential combination chemotherapy with vinblastine/bleomycin and adriamycin/cis-dichlorodiammineplatinum (II) in non-seminomatous testicular cancer. I. Results of a prospective randomized phase III-study with 71 patients with disseminated disease (stage IV) (author's transl)].

Authors:  M E Scheulen; M Higi; R B Schilcher; C R Meier; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1980-08-15

7.  [Side-effects of polychemotherapy in metastatic testicular neoplasms (author's transl)].

Authors:  J H Hartlapp; N Jaeger; P Fischer; L Weissbach
Journal:  Klin Wochenschr       Date:  1982-03-01

Review 8.  Update in cancer chemotherapy: genitourinary tract cancer, Part 4: Testicular cancer.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-04       Impact factor: 1.798

9.  A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature.

Authors:  Patricia A Demoor; Yuri Matusov; Colleen Kelly; Shobha Kolan; Linda Barnachea; Lyudmila A Bazhenova
Journal:  J Cancer       Date:  2011-03-10       Impact factor: 4.207

10.  Chemotherapy of advanced malignant teratomas.

Authors:  E S Newlands; R H Begent; S B Kaye; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1980-09       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.